Halozyme Therapeutics President and CEO Helen Torley Sells $6M of Stock
Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $96.85 to $101.72 a share (average $100.01) in 10 transactions, worth $6M in total between Nov 12, 2026 and Nov 16, 2026. Shares held after the trade: 767,780 (-0.0%).
Halozyme Therapeutics reported strong growth for the third quarter of 2026, with total revenues increasing to $493.0 million compared to $354.3 million in the prior year, driven primarily by higher royalty and product sales. Net income rose to $247.0 million, while the company significantly restructured its debt through the issuance of 2033 Convertible Notes and the repayment of 2027 and 2028 notes.
Halozyme Therapeutics reported record Q3 2026 financial results with total revenue increasing 39% year-over-year to $493 million, driven by a 44% surge in royalty revenue. Based on strong performance, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and non-GAAP EPS while highlighting a legal victory in the Netherlands protecting its intellectual property against Merck.
Term
Q3 2026
“Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels.”
Dr. Helen Torley, President and Chief Executive Officer
“Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026.”
Darren Snellgrove, Executive Vice President and Chief Financial Officer